secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001689548-22-000124
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis Q3 2022 net loss $43.9M; cash $123.7M; PRAX-944 top-line results expected 1Q23
--------------------------------------------------------------------------------

- Net loss $43.9M vs $44.7M YoY; R&D expenses $30.4M down from $33.1M.
- Cash and investments $123.7M, down from $275.9M at year-end 2021; runway into 1Q24.
- PRAX-944 Phase 2b Essential1 top-line results for essential tremor expected 1Q23; screening to complete mid-Nov 2022.
- PRAX-222 EMBRAVE study for SCN2A-DEE to initiate in 4Q22; initial dose cohort results expected 2023.
- PRAX-114 Phase 2 Acapella study in MDD not statistically significant; no further development planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954822000124/0001689548-22-000124-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954822000124/prax-20221109.htm
  HTML page:      https://secwatch.observer/filing/0001689548-22-000124

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer